

Alan List, MD is a hematologist and physician scientist who is internationally recognized. for his many contributions in the development of more effective treatment strategies for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). He received his medical degree from Perelman School of Medicine at the University of Pennsylvania and has been in practice for more than 30 years. His pioneering work led to the development of lenalidomide (Revlimid®) from the laboratory to clinical trials, which went on to receive fast-track designation from the U.S. Food and Drug Administration and approval for the treatment of patients with deletion 5q MDS and multiple myeloma. This work transformed the natural history of Del(5q) MDS by suppressing all manifestations of the disease and sustaining remissions for years. His most recent laboratory studies demonstrated that the impairment in blood production in MDS arises from innate immune activation resulting in a novel, previously unrecognized inflammatory form of cell death termed pyroptosis. Dr. List was also a key leader in the development and FDA approval of two other agents for MDS, i.e., azacitidine (Vidaza®) and most recently, luspatercept (Reblozyl®).

He is the author of more than 450 peer-reviewed manuscripts, chapters and books. He is the former President and CEO of Moffitt Cancer Center, and serves as a member of the Myelodysplastic Syndromes (MDS) Foundation Board of Directors and is the immediate past president (2017-18) of the Society of Hematologic Oncology. He has served on the scientific advisory boards of the Cellular Biomedicine Group and Aileron Therapeutic, Inc. since 2016 and 2018, respectively. Dr. List has received many awards and recognitions for his research including the General Motors Cancer Research Foundation-Merit Award, the J.P. McCarthy Foundation International Prize, the Emil J. Freireich Award for Clinical Research, the Joshua Lederberg Society, the Grinberg-Wisch Mount Sinai Award, the Celgene Lifetime Achievement Award in Hematology, the Aplastic Anemia & MDS International Foundation Leadership in Science Award, Giants of Cancer Care Awards and others. List is a Charter Fellow of the National Academy of Inventors (NAI) and holds 18 U.S. patents with more than 45 patent applications.